Two newly-approved antiviral drugs against COVID are now available to those who need them. But the FDA is getting in the way with unwise and counterproductive requirements. Drs. Jeffrey Singer and Josh Bloom explain in their Op Ed in the New York Daily News.
We Have New Covid Drugs- FDA Needs to Get Out of the Way. Drs. Singer and Bloom in the NY Daily News
All of a sudden we have two (provisionally) FDA-approved COVID antivirals, which will be in pharmacies soon. They are quite different. Which is best for you?
We are fortunate enough that there is now an FDA-approved drug called Paxlovid, which does an incredible job of keeping COVID patients out of the hospital (or morgue). Yet NBCNews.com chose a sensationalist, scary headline about the drug as its lead health story of the day. Really lousy journalism.
It was pretty much a forgone conclusion, but the FDA's decision to grant an Emergency Use Authorization to Pfizer's COVID drug, Paxlovid, could mark the turning point in our battle against the virus. Here's the story that you won't find anywhere in the press.
A new rumor claims that Paxlovid, Pfizer's Covid drug, is merely a "dressed up" ivermectin molecule with little difference other than price. The term "Pfizermectin" is even being used to emphasize this. But biochemical and pharmacokinetic data say otherwise. Here are the numbers.
Pfizer's Paxlovid looks very promising in fighting COVID. It also provides a good opportunity to learn about how enzyme inhibitors work. For masochists only.
We're almost two years into the pandemic and there have been more than enough ups and downs to last a lifetime. But now we have a potentially big "up," because the results just came in on Pfizer's COVID drug Paxlovid—and they are nothing short of amazing. Will we finally be free of the terror of this pandemic? Maybe.